Tissue Plasminogen Activator Market 2019 | Industry Insights by Top Players Bayer AG, Abcam, Calbiochem, Merck & Company, Roche, Sekisui Diagnostics, Genentech, Sigma-Aldrich, Taj Pharmaceuticals, Cadila Healthcare Ltd.

Tissue plasminogen activator (tPA) is an enzyme associated with the disintegration of blood clots. It is a serine protease present in endothelial cells. With the help of serine protease, the conversion of plasminogen to plasmin is catalyzed. Serine protease is a major enzyme for clot disintegration.

tPA is also be produced by using recombinant technology techniques known as recombinant tissue plasminogen activator (rtPA). Specific rtPAs are tenecteplase, alteplase, and reteplase. These enzymes are used in clinical treatment of thrombotic stroke or embolic stroke. tPA is a drug that dissolves blood clots. It is a thrombolytic agent which can be administrated into the veins.

Free Request Sample of Report: https://www.coherentmarketinsights.com/insight/request-sample/2469

Global Tissue Plasminogen Activator Market: Drivers

Tissue plasminogen activator is the first and only drug approved by the FDA in 1996 for the treatment of acute ischemic stroke. Increasing incidences of stroke has boosted the tissue plasminogen activator market size. According to John Hopkins Medicines (JHM) in the U.S., around 795,000 people in the U.S. suffer from stroke per year, as reported in 2014. According to the World Health Organization (WHO), stroke is the second leading cause of death and the third leading cause of disability, worldwide, as reported in 2012. This is one of the major factors driving the tissue plasminogen activator market growth.

Increasing prevalence of stroke incidences in growing geriatric population is another major factor driving the market size. As per the Public Health England (PHE), around 38% of people suffering from strokes were aged 40 to 69 in 2018. Moreover, tissue plasminogen activator market revenue is witnessing further increase due to awareness about stroke and its symptoms. In 2015, the Centers of Disease Control and Prevention (CDC) stated that around 38% of people were able to recognize the major symptoms of stroke and were treated at the right time.

Global Tissue Plasminogen Activator Market: Regional Analysis

North America is the leader in the global tissue plasminogen activator market, owing to rising awareness about stroke and huge spending on treatment of stroke. For instance, in 2017, the American Heart Association (AHA) recorded stroke costs as US$ 34 billion in the U.S. every year, which includes medicines for the treatment of stroke and cost of health care services.

Asia pacific is the fastest growing region in the tissue plasminogen activator market, owing to increasing demand drug coupled with rising stroke incidences in the region. According to WHO, Indonesia, Philippines, China, and India have highest rates of stroke, which is 186.3, 134.7, 128, and 71.5, respectively, as recorded in 2017.

Get Free PDF Brochure of Research Report: https://www.coherentmarketinsights.com/insight/request-pdf/2469

Global Tissue Plasminogen Activator Market: Competitive Landscape

Key players operating in the global tissue plasminogen activator market include Bayer AG, Abcam, Calbiochem, Merck & Company, Roche, Sekisui Diagnostics, Genentech, Sigma-Aldrich, Taj Pharmaceuticals, and Cadila Healthcare Ltd.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

This release was published on openPR.